

SEPTEMBER 2025

Date	Headline and Source	Link	Summary
1 st September	23 of top 50 life sciences companies anchor GCCs in India The Times of India, September 01, 2025	23 of top 50 life sciences companies anchor GCCs in India	Recent investments underscore this shift. Sanofi announced a € 400 million expansion of its Hyderabad GCC to double its workforce and develop its largest global hub, powered by AI and digital platforms for R&D, manufacturing, and commercial operations.
2 nd September	Novo Nordisk, Apollo Clinics partner to launch obesity clinic program in India Express Healthcare, September 02, 2025	Novo Nordisk, Apollo Clinics partner to launch obesity clinic program in India	Novo Nordisk announced a strategic collaboration with Apollo Clinics to launch a comprehensive Obesity Management Program across various cities in India. This initiative aims to address the growing burden of overweight and obesity through a structured, multitiered care model focused on empowering individuals living with overweight or obesity and developing specialised programs for obesity care.
3 rd September	Bayer enters prenatal nutrition segment with Supradyn Mom's and Naturals Calcium+ Media Brief, September 03, 2025	Bayer enters prenatal nutrition segment with Supradyn Mom's and Naturals Calcium+	In celebration of National Nutrition Week, Bayer's Consumer Health Division announces its entry into the prenatal nutrition segment with the launch of Supradyn Mom's and Supradyn Naturals Calcium+, under its multivitamin brand Supradyn®. This range is designed to address the nutritional deficiencies faced by women in India during preconception, pregnancy, and lactation.
5 th September	GST cut on drugs medical devices to provide relief to patients Industry players The Economic Times, September 05, 2025	GST cut on drugs medical devices to provide relief to patients Industry players	Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai said, The decision to reduce GST on lifesaving medicines bringing 33 essential drugs from 12 per cent to nil and three critical drugs for cancer, rare diseases, and other severe chronic conditions from 5 per cent to nil is both historic and compassionate
5 th September	GST cut on drugs medical devices to provide relief to patients Industry players The Week, September 05, 2025	GST cut on drugs medical devices to provide relief to patients Industry players	Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai said, The decision to reduce GST on lifesaving medicines bringing 33 essential drugs from 12 per cent to nil and three critical drugs for cancer, rare diseases, and other severe chronic conditions from 5 per cent to nil is both historic and compassionate.

5 th September	DoP eases compliance under UCPMP 2024 Express Pharma, September 05, 2025	DoP eases compliance under UCPMP 2024	Anil Matai, Director General, OPPI said We welcome the Department of Pharmaceuticals updated guidelines under the amended UCPMP, 2024, which bring greater clarity and streamlining to compliance requirements for the industry.
5 th September	DPIIT signs MoU with Pfizer Limited to strengthen India's healthcare innovation ecosystem News On Air, September 05, 2025	DPIIT signs MoU with Pfizer Limited to strengthen India's healthcare innovation ecosystem	Department for Promotion of Industry and Internal Trade (DPIIT) today signed a Memorandum of Understanding with Pfizer Limited In a statement, the Ministry of Commerce and Industry said that the collaboration will accelerate the labtomarket journey of innovative healthcare products by extending financial and nonfinancial support to startups
7 th September	Tamil Nadu signs MoUs worth Rs 15,516 crore across UK and Germany The Hindu Business Line, September 07, 2025	Tamil Nadu signs MoUs worth Rs 15,516 crore across UK and Germany	AstraZeneca also announced its third strategic investment in Tamil Nadu within two years a Rs 176 crore expansion of its Global Innovation & Technology Centre (GITC) in Chennai. On September 1, commercial vehicle manufacturer Ashok Leyland announced plans to invest over Rs 5,000 crore towards the development and manufacturing of next-generation batteries.
9 th September	OPPI sees reducing processing time from 90 to 45 days for BA/BE studies to boost faster access to medication PharmaBiz, September 09, 2025	OPPI sees reducing processing time from 90 to 45 days for BA/BE studies to boost faster access to medication	Organisation for Pharmaceutical Producers of India (OPPI) sees reducing processing time from 90 to 45 days for BA/BE studies to boost faster access to medication. This follows with the Union government to the proposal to amend the New Drugs and Clinical Trials Rules, 2019 (NDCT), to promote ease of doing business.
11 th September	Novo Nordisk Gets CDSCO Panel Nod for Rybelsus Label Update, Aligned with EMA Medical Dialogues, September 11, 2025	Novo Nordisk Gets CDSCO Panel Nod for Rybelsus Label Update, Aligned with EMA	The decision came during the SEC meeting held on August 20, 2025, at CDSCO headquarters in New Delhi. Novo Nordisk presented its proposal to update the package insert (Version February 2025) in line with the European Medicines Agency (EMA) approval.
11 th September	AstraZeneca launches Eculizumab in India Express Pharma, September 11, 2025	AstraZeneca launches Eculizumab in India	AstraZeneca India has launched Eculizumab concentrate solution for infusion (300 mg,10 mg/ml) in India. This follows the Central Drugs Standard Control Organisation (CDSCO) approval received in January 2025 for the import, sale, and distribution of the product.
12 th September	AstraZeneca Gets SEC Approval to Conduct Phase IV Trial of Hyperkalemia	AstraZeneca Gets SEC Approval to Conduct Phase IV Trial of	The Subject Expert Committee (SEC) functioning under the Central Drug Standard Control Organisation (CDSCO),

	Drug Sodium Zirconium Cyclosilicate Medical Dialogues, September 12, 2025	Hyperkalemia Drug Sodium Zirconium Cyclosilicate	has granted approval to the drug major AstraZeneca Pharma India to conduct a Phase-IV Clinical trial of Sodium Zirconium Cyclosilicate powder for oral Suspension 5/ 10 g, used to treat hyperkalemia.
14 th September	Roche Pharma trains 400 professionals across 10 government hospitals The Echo of India, September 14, 2025	Roche Pharma trains 400 professionals across 10 government hospitals	Roche Pharma India today announced the successful completion of Phase One of its Advanced Inclusive Research (AIR) Site Alliance initiative. The program partnered with 10 leading government hospitals nationwide and trained nearly 400 professionals including investigators, ethics committee members, and support staff - to global Good Clinical Practice (GCP) standards
14 th September	Roche Pharma India completes 1st phase of Advanced Inclusive Research (AIR) site alliance The Economic Times, September 14, 2025	Roche Pharma India completes 1st phase of Advanced Inclusive Research (AIR) site alliance	Roche Pharma India has announced the completion of the first phase of its Advanced Inclusive Research (AIR) Site Alliance initiative in the country. The program partnered with 10 leading government hospitals and trained nearly 400 professionals, including investigators, ethics committee members, and support staff, to meet global Good Clinical Practice (GCP) standards.
16 th September	Roche partners with 10 govt hospitals to strengthen clinical trial capabilities in India BioSpectrum India, September 16, 2025	Roche partners with 10 govt hospitals to strengthen clinical trial capabilities in India	Roche Pharma India has announced the successful completion of the first phase of its Advanced Inclusive Research (AIR) Site Alliance initiative in India, having partnered with 10 leading government hospitals from across the country and trained nearly 400 professionals including investigators, ethics committee members and support staff to global Good Clinical Practice (GCP) standards.
16 th September	Cell therapy's next chapter: Industry embraces invivo innovation Express Pharma, September 16, 2025	Cell therapy's next chapter: Industry embraces invivo innovation	AbbVie acquires Capstan Therapeutics for \$2.1 billion: AbbVie's acquisition of Capstan signals intent to lead in mRNA/LNP technology, the same technique behind COVID-19 vaccines, now adapted for cancer. AstraZeneca buys EsoBiotec for \$425 million: AstraZeneca expands its oncology pipeline and in vivo capabilities by acquiring a major player in nonviral gene delivery.
19 th September	Pharma GCCs: Where back offices become brains trust The Times of India, September 19, 2025	Pharma GCCs: Where back offices become brains trust	Anil Matai, director general of the Organisation of Pharmaceutical Producers of India (OPPI), says what makes India unique is its positioning at the convergence of world-class scientific

			talent, robust digital infrastructure and a thriving innovation mindset.
19 th September	After Mounjaro Jab, Eli Lilly plans weight loss pill launch in India The Economic Times, September 19, 2025	After Mounjaro Jab, Eli Lilly plans weight loss pill launch in India	US pharma major Eli Lilly is setting its sights on launching an oral version of its experimental weight loss drug orforglipron, building on the successful introduction of its weight-loss injectable Mounjaro (tirzepatide) in India in March this year.
22 nd September	Healthcare set to be more affordable as new GST rate kicks in from Sep 22: Pharma industry The Economic Times, September 22, 2025	Healthcare set to be more affordable as new GST rate kicks in from Sep 22: Pharma industry	Earlier, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai had stated that the decision to reduce GST on lifesaving medicines bringing 33 essential drugs from 12 per cent tax slab to nil and three critical drugs for cancer, rare diseases, and other severe chronic conditions from 5 per cent to nil is both historic and compassionate.
23 rd September	Healthcare set to be more affordable Bizz Buzz, September 23, 2025	Healthcare set to be more affordable	Earlier, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai had stated that the decision to reduce GST on lifesaving medicines bringing 33 essential drugs from 12 per cent tax slab to nil and three critical drugs for cancer, rare diseases, and other severe chronic conditions from 5 per cent to nil is both historic and compassionate.
25 th September	AbbVie Hosts National Conclave on World Retina Day to Spotlight Rising Burden of Diabetic Macular Edema The Hans India, September 25, 2025	AbbVie Hosts National Conclave on World Retina Day to Spotlight Rising Burden of Diabetic Macular Edema	Delhi AbbVie, a global biopharmaceutical leader committed to developing innovative medicines and solutions, hosted the National Conclave on World Retina Day at the India Habitat Centre, Delhi, to spotlight Diabetic Macular Edema (DME), one of the leading causes of vision loss among people living with diabetes.
26 th September	Eli Lilly plans to launch experimental weight-loss pill in India, executive says Money Control, September 26, 2025	Eli Lilly plans to launch experimental weight-loss pill in India, executive says	The drugmaker has bid for approval for the experimental pill after latest clinical data showed it lowered average blood sugar and weight in a head-to-head trial of adults with type-2 diabetes more effectively than rival Novo Nordisk's older GLP-1 pill Rybelsus.(NOVONOR DISK)
26 th September	Eli Lilly plans to launch experimental weight-loss pill in India, says executive The Economic Times, September 26, 2025	Eli Lilly plans to launch experimental weight-loss pill in India, says executive	Eli Lilly plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world's most populous nation, a senior executive said on Thursday. "I do think there is promise for products like that (orforglipron) in India, if it does get approved," Winselow Tucker, Lilly India's president said at an event in Mumbai.

27 th September	India's elderly need more than respect, they need urgent policy focus ETHealthworld, September 27, 2025	India's elderly need more than respect, they need urgent policy focus	India's reverence and respect for elders is undeniable, but often, healthy ageing remains highly uneven, relying on luck, resources, and family support rather than a deliberate, system-wide approach. As a caregiver to octogenarian parents and professional experience of three decades in the healthcare industry, every day, I witness and experience the challenges, the resilience, and the yearning for graceful ageing of our elderly.
28 th September	India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges Business Standard, September 28, 2025	India to get Novo Nordisk's Ozempic soon as demand for obesity drugs surges	Competition with Eli Lilly Ozempic will compete directly with US pharma giant Eli Lilly's Mounjaro, launched in India in March According to PharmaTrac, Mounjaro recorded sales of Rs 154 crore in its first five months, while Wegovy achieved Rs 19 crore in three months
30 th September	Ozempic approved in India, Novo Nordisk country head says much-needed India Today, September 30, 2025	Ozempic approved in India, Novo Nordisk country head says much-needed	Danish drugmaker Novo Nordisk is set to launch Ozempic (semaglutide) in India, a move that will benefit patients suffering from Type 2 Diabetes in the country, says India Head, Vikrant Shrotiya, in an exclusive conversation with India Today.
30 th September	AbbVie hosts National Conclave on World Retina Day to address Diabetic Macular Edema Media Brief, September 30, 2025	AbbVie hosts National Conclave on World Retina Day to address Diabetic Macular Edema	Suresh Pattathil, Managing Director & General Manager, AbbVie India, said, At AbbVie, we are proud to leverage over 75 years of global eyecare expertise to make a meaningful difference for the 3 million people living with Diabetic Macular Edema (DME) in India.
